Kotra Industries Bhd
Kotra Industries Bhd operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.
Business. Kotra Industries Bhd (KOIN.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Kotra Industries Bhd (KOIN.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Kotra Industries Bhd maintains a strong liquidity position, with a current ratio of 2.9, indicating the company can cover its short-term liabilities more than two times over. However, the company reported negative free cash flow of MYR -30.23 million, primarily due to capital expenditures of MYR -35.98 million, which exceeded operating cash flow of MYR 45.91 million. The company's debt-to-equity ratio is effectively zero, as long-term debt is minimal at MYR 326,000, suggesting a conservative capital structure.
Profitability metrics for Kotra Industries Bhd show a return on equity (ROE) of 2.6% and a return on assets (ROA) of 2.17%. These figures are below the industry median for pharmaceutical companies, which typically report ROE and ROA in the 5-8% range. The company's net income of MYR 6.83 million on revenue of MYR 55.88 million results in a net margin of 12.2%, which is in line with the industry average.
Geographically, Kotra Industries Bhd's revenue is concentrated in Malaysia, with no disclosed international operations. The company's business is primarily driven by domestic demand for pharmaceutical products, which exposes it to local economic conditions and regulatory changes. The company operates in a single business segment, focusing on pharmaceuticals, with no material diversification into other healthcare subsectors.
Looking ahead, Kotra Industries Bhd is projected to maintain stable revenue growth, with analysts forecasting a mean price target of MYR 4.90 per share. The company's operating income of MYR 13.91 million and net income of MYR 6.83 million suggest a solid earnings base, but the negative free cash flow indicates ongoing investment in capital expenditures. The company's revenue has remained relatively stable in recent periods, with no significant year-over-year growth reported.
Risk factors for Kotra Industries Bhd include liquidity concerns, as the company has negative net cash after subtracting total debt. While the company's debt levels are low, the negative free cash flow could limit its ability to fund operations or pursue growth opportunities without external financing. The risk of dilution is currently low, as the number of shares outstanding has not changed between basic and diluted shares. However, the company's capital expenditures may require additional financing in the future, which could lead to share dilution or increased debt.
Recent events for Kotra Industries Bhd include the publication of its latest financial results, which show a stable revenue base and moderate profitability. The company has not disclosed any major strategic initiatives or new product launches in recent filings. Analysts have issued a single "buy" recommendation, with no strong buy or hold ratings, indicating a cautious outlook for the stock.
- Kotra Industries Bhd has a strong current ratio of 2.9 but reports negative free cash flow due to high capital expenditures.
- The company's ROE and ROA are below the industry median, indicating room for improvement in profitability.
- Revenue is concentrated in Malaysia, with no international diversification, exposing the company to local economic and regulatory risks.
- Analysts have issued a single "buy" recommendation, with a mean price target of MYR 4.90 per share.
- The company's low debt-to-equity ratio and minimal long-term debt suggest a conservative capital structure.
Bull / Bear case
Generated · model-assistedAnalysts project 21% upside to a target price of MYR 4.90, reflecting positive market sentiment.
Revenue grew at a 9.7% CAGR over four years, showing consistent top-line expansion capability.
The company maintains a zero debt-to-equity ratio, providing a strong balance sheet with minimal leverage risk.
Free cash flow turned negative to MYR -20.4 million in FY2025, signaling potential liquidity or investment pressures.
Net income declined 4.8% year-over-year to MYR 42.5 million, indicating weakening profitability trends.
The company faces medium liquidity risk, which could constrain operational flexibility or dividend sustainability.
In focus — financials by report
Revenue MYR 230.8M, +1,9% YoY; Operating income −9,4% YoY.
- ▍Revenue MYR 230.8M, +1,9% YoY
- ▍Operating income −9,4% YoY
- ▍Net income −4,8% YoY
- ▍Free cash flow +35,9% YoY
- ▍Net margin 18.4%
Revenue MYR 226.6M, −6,5% YoY; Operating income −15,4% YoY.
- ▍Revenue MYR 226.6M, −6,5% YoY
- ▍Operating income −15,4% YoY
- ▍Net income −31,6% YoY
- ▍Free cash flow −443,8% YoY
- ▍Net margin 19.7%
Revenue MYR 242.2M, +16,5% YoY; Operating income +16,1% YoY.
- ▍Revenue MYR 242.2M, +16,5% YoY
- ▍Operating income +16,1% YoY
- ▍Net income +5,1% YoY
- ▍Free cash flow −77,5% YoY
- ▍Net margin 26.9%
Revenue MYR 207.9M, +30,3% YoY; Operating income +109,5% YoY.
- ▍Revenue MYR 207.9M, +30,3% YoY
- ▍Operating income +109,5% YoY
- ▍Net income +154,6% YoY
- ▍Free cash flow +52,0% YoY
- ▍Net margin 29.9%
Revenue MYR 159.6M; Operating income MYR 27.4M.
- ▍Revenue MYR 159.6M
- ▍Operating income MYR 27.4M
- ▍Net margin 15.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,33 |
| Revenue | —no estimate | —no estimate | 275,1M MYR |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Kotra Industries Bhd Market data — financials · 2026-05-28
- Kotra Industries Bhd Market data — analyst estimates · 2026-05-28